Zealand Pharma starts registrational Phase 3 ZUPREME for petrelintide
Zealand Pharma said it has initiated the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity.
Zealand Pharma said it has begun the registrational Phase 3 ZUPREME program for petrelintide in people with overweight or obesity. The company said the release is No. 17 / 2026 and is dated September 22, 2026. The announcement identifies Zealand Pharma A/S, NASDAQ:ZEAL, CVR-no.
20045078, as the company behind the program.